Also EGFR/HER-2 inhibition by the dual inhibitor lapatinib resulted in enhanced radiosensitivity in cancer cells of various entities, such as bladder cancer, peripheral nerve sheath tumors, pancreatic or breast cancer. This evidence concerns the gene EGFR and urinary bladder carcinoma.